Merck ADC cuts death risk by one-third in advanced endometrial cancer

Merck and Kelun-Biotech's antibody-drug conjugate met its primary endpoint in a Phase 3 trial, reducing mortality by one-third in advanced endometrial cancer. This is a positive late-stage readout for a novel targeted therapy, though regulatory and commercial implications remain. The result strengthens Merck's oncology pipeline and validates the ADC platform.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works